Adaptimmune announced the closing of its initial public offering of 11,250,000 American Depositary Shares at a price to the public of $17.00 per ADS.
The aggregate net proceeds to Adaptimmune, after underwriting discounts and commissions and estimated offering expenses, were approximately $175.7 million.
|Searching for more deal information? Current Partnering offers the following options:|
- CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
- Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
- CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time
As previously reported, Adaptimmune has granted the underwriters a 30-day option to purchase up to an additional 1,687,500 ADSs.